tesamorelin vs cjc-1295

updated October 25, 2026

tesamorelin (tier S) vs cjc-1295 (tier A): what each is, why each got its grade, half-life and source counts side by side.

tesamorelin · tier S

the FDA-approved injection that targets visceral fat. the dangerous kind.

tier rationale

different mechanism than GLP-1s. tesa tells your pituitary to pulse growth hormone, which mobilizes visceral fat. clean, targeted, documented. FDA-approved since 2010 for HIV-associated lipodystrophy. long-term cardiovascular safety still uncertain. increasingly used off-label by men 40+ for body recomp. S because drug-tier human trial data exists. narrow indication and high cost keep it niche.

cjc-1295 · tier A

growth hormone without injecting growth hormone. tells your pituitary to make its own. paired with ipamorelin.

tier rationale

a synthetic GHRH analog engineered by ConjuChem to have a dramatically extended half-life, achieved by covalent binding to endogenous albumin via a drug affinity complex (DAC). comes in two forms: with DAC (6-8 day half-life, single weekly dose) and without DAC (short-acting, "Mod GRF 1-29," used in stacked protocols). the GHRH-receptor agonism mechanism is well-characterized, but a phase 2 HIV-lipodystrophy trial was discontinued after a patient death (attending physician concluded unrelated). A-tier based on mechanism plausibility and consistent user reports from peptide clinics, held back from S by the absence of a completed clinical program and no FDA approval.

at a glance

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.